Total Funding
81
79
Total FundingPost-IPO Debt raised
Growth Score
-2 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
15629
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Chieze Ibeneche-Nnewihe: Director, Business Development and Corporate StrategyPast Role: RA Capital Management, Venture Associate
Geoff Nichol: CMO & SVP, Global Clinical Development
About the Company
BioMarin Pharmaceutical develops and delivers therapies for rare genetic and metabolic conditions. The company applies scientific research to understand the underlying causes of diseases and creates medicines using multiple treatment approaches.Its portfolio includes therapies for achondroplasia, severe hemophilia A, and various lysosomal storage
disorders. BioMarin conducts clinical and preclinical research to expand its pipeline of investigational treatments. The company emphasizes collaboration with patient communities to inform therapy development and focuses on translating genetic discoveries into potential new medicines. Its operations encompass research, development, and manufacturing of specialized therapies for complex conditions.
